Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1995-06-07
1998-12-08
Fitzgerald, David L.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
435 697, C07K 14435, C12N 1562
Patent
active
058470824
ABSTRACT:
Nucleic acid sequences encoding chimeric proteins that comprise a functional portion of a parent terminal complement inhibitor, such as CD59, and a heterologous transmembrane domain are provided. The parent terminal complement inhibitor is modified to inactivate its GPI signal sequence. The heterologous transmembrane domain serves to anchor the chimeric protein to the cell membrane without substantially interfering with the complement inhibitor activity of the terminal complement inhibitor. The nucleic acid sequences and encoded chimeric proteins can be used to protect cells from complement attack.
REFERENCES:
patent: 5521066 (1996-05-01), Menzel et al.
patent: 5550108 (1996-08-01), Sims et al.
patent: 5573940 (1996-11-01), Sims et al.
patent: 5624837 (1997-04-01), Fodor et al.
patent: 5627264 (1997-05-01), Fodor et al.
patent: 5660825 (1997-08-01), Sims et al.
patent: 5705732 (1998-01-01), Sims et al.
Su et al J. Cell Biol. vol. 112 (3) pp.377-384, Feb. 1991.
Albrecht, et al., 1992. "Herpesvirus Saimiri Has a Gene Specifying a Homologue of the Cellular Membrane Glycoprotein CD59" Virology 190:527-530.
Brown, et al., 1992. "Sorting of GPI-Anchored Proteins to Glycolipid- Enriched Membrane Subdomains during Transport to the Apical Cell Surface" Cell. 68:533-544.
Butikofer, et al., 1989. "Enrichment of Two Glycosyl-Phosphatidylinositol-Anchored Proteins, Acetylcholinesterase and Decay Accelerating Factor, in Vesicles Released form Human Red Blood Cells" Blood. 74:1481-1485.
Cinek, et al., 1992. "The nature of large noncovalent complexes containing glycosylphosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases" J. Immunol. 149:2262-2270.
Davies, et al., 1989. "CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells" J. Exp. Med. 170:637-654.
Ferguson, et al., 1988. "Cell-Surface Anchoring of Proteins via Glycosyl-Phosphatidylinositol Structure" Ann. Rev. Biochem., 57:285-320.
Holguin, et al., 1989. "Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria" J. Clin. Invest. 84:7-17.
Lublin, et al., 1991. "Phospholipid-anchored and Transmembrane Versions of Either Decay-Accelerating Factor or Membrane Cofactor Protein Show Equal Efficiency in Protection from Complement-mediated Cell Damage" J. Exp. Med., 174:35-44.
McMahon, et al., 1989. "Ectopic Expression of the Proto-Oncogene int-1 in Xenopus Embryos Leads to Duplication of he Embryonic Axis" Cell. 58:1075-1084.
Meri, et al., 1990. "Human protection (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers" Immunology 71:1-9.
Moran, et al., 1992. "Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo" J. Immunol. 140:1736-1743.
Nakano, et al., 1993. "Expressions and Characterizations of Recompinant MACIFs (CD59) of Three Different Lengths" Molec. Immunol. 30(suppl. 1):37.
Norris, et al., 1993. "Structure-Function Relationships of CD59" Blood, 82(suppl.):202a.
Okada, et al., 1989. "Monoclonal Antibodies Capable of Causing Hemolysis Of Neuraminidase-Treated Human Erythrocytes by Homologus Complement" J. Immunol. 143:2262-2266.
Okada, et al., 1989. "20 KDa Homologous Restriction Factor of Complement Resembles T Cell Activating Protein" Biochem. Biophys. Res. Commun. 162: 1553-1559.
Petranka, et al., 1993. "The Structure and Function fo CD59 : The Importance of the Disulfide Structure and Identification of a Primary Epitope" Molec. Immunol. 30(suppl. 1):44.
Philbrick, et al., 1990. "The CD59 Antigen Is A Structural Homologue of Murine Ly-6 Antigens but Lacks Interferon Inducibility" Eur. J. Immunol. 20:87-92.
Purcell, et al., 1991. "Alternatively Spliced RNAs Encode Several Isoforms of CD46 (MCP), A Regulator of Complement Activation" Immunogenetics 33:335-344.
Rollins, et al., 1990. "The Complement-Inhibitory Activity of Cd59 Resides in its Capacity to Block Incorporation of C9 into Membrane C5b-9" J. Immunol. 144:3478-3483.
Rollins, et al., 1991. "Inhibition of Homologous Complement by CD59 is Mediated by A Species-Selective Recognition Conferred Through Binding to C8 within C5b-8 or C9 within C5b-9" J. Immunol. 146:2345-2351.
Rother, et al., 1994. "Inhibition of Complememt-Mediated Cytolysis by the terminal Complement Inhibitor of Herpesvirus Saimiri" J. Virol. 68:730-737.
Sawada, et al., 1990. "Isolation and Expression of the Full-Length cDNA Encoding CD59 Antigen of Human Lymphocytes" DNA and Cell. Biol. 9:213-220.
Seaman, et al., 1991. "Molecular Cloning of gp42, a Cell-Surface Molecle That Is Selectively Induced on Rat Natural Killer Cells by Interleukin 2: Glycolipid Membrane Anchoring and Capacity for Transmembrane Signaling" J. Exp. Med. 173:251-260.
Stefanova, et al., 1989. "Characterization of a Broadly Expressed Human Leucocyte Surface Antigen MEM-43 Anchored in Membrane Through Phosphatidylinositol" Mol. Immunol. 26:153-161.
Su, et al., 1991. "The Glycolsyl Phosphatidylinositol Anchor Is Critical for Ly-6A/E-Mediated T Cell Activation" J. Cell Biol. 112:377-384.
Suter, et al., 1992. "NGF/BDNF Chimeric Proteins: Analysis of Neurotrophin Specificity by Homolog-scanning Mutagenesis" J. Neurosci. 12:306-318.
Tone, et al., 1992. "Gene Structure of Human CD59 and Demonstration that Discrete mRNAs Are Generated by Alternative Polyadenylation" J. Mol. Biol. 227:971-976.
Venneker, et al., 1992. "CD59: A Molecule Involved in Antigen Presentation as well as Downregulation of Membrane Attack Complex" Exp. Clin. Immunogenet. 9:33-47.
Walsh, et al., 1991. "Transfection of Human CD59 Complementary DNA into Rat Cells Confers Resistance to Human Complement" Eur. J. Immunol. 21:847-850.
Whitlow, et al., 1991. "H19, a Surface Membrane Molecule Involved in T-Cell Activation, Inhibits Channel Formation by Human Complement" Cell Immunol. 126:176-184.
Whitlow, et al., 1993. "Cells Lacking Glycan Phosphatidylinositol-Linked Proteins Have Impaired Ability to Vesiculate" Blood. 81:510-516.
Wing, et al., 1992. "Oligodendrocytes Lack Glycolipid Anchored Proteins which Protect them against Complement Lysis by Incorporation of CD59" Immunology. 76:140-145.
Zalman, et al., 1986. "Isolation of a Human Erythrocyte Memebrane Protein Capable of Inhibiting Expression of Homologous Complemennt Transmembrane Channels" Proc. Natl. Acad. Sci. USA. 83:6975-6979.
Zhao, et al., 1991. "Amplified Gene Expression in CD59-Transfected Chinese Hamster Ovary Cells Confers Protection against the Membrane Attack Complex of Human Complement" J. Biol. Chem. 266:13418-13422.
Lehto, et al., 1993. "Interactions of Soluble CD59 with the Terminal Complement Complexes: CD59 and C9 Compete for A Nascent Epitope on C8" J. Immunol. 151:4941-4949.
Okada et al., 1990. "Erythrocytes of Patients with Paroxysmal Nocturnal Haemoglobinuria Acquire Resistance to Complement Attack by a Purified 20-kD Homologous Restriction Factor" Clin. Exp. Immunol. 80:109-113.
Rooney et al., 1992. "Characterization of the Membrane Attack Complex Inhibitory Protein CD59 Antigen on Human Amniotic Cells and in Amniotic Fluid" Immunol. 76:541-547.
Waneck et al., 1988. "Conversion of a PI-Anchored Protein to an Integral Membrane Protein by a Single Amino Acid Mutation" Science. 24:697-699.
Rotoli et al., 1989, "Paroxysmal Nocturnal Hemoglobinuria" Seminars in Hematology, vol. 26, pp. 201-207.
Rollins Scott
Rother Russell
Squinto Stephen P.
Alexion Pharmaceuticals, Inc.
Bagham Daryl A.
Fidel, Ph.D. Seth A.
Fitzgerald David L.
Klee Maurice M.
LandOfFree
Terminal complement inhibitor fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Terminal complement inhibitor fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Terminal complement inhibitor fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-178239